[Combination of interferon-alpha and all-trans-retinoic acid as a treatment for maintaining remission in high-risk group patients with acute myeloid leukemia]. / Sochetanie interferona-alpha i polnost'iu trans-retinoevoi kisloty v kachestve programmy terapii podderzhaniia remissii u bol'nykh ostrymi mieloidnymi leikozami iz gruppy vysokogo riska.
Ter Arkh
; 73(7): 15-20, 2001.
Article
em Ru
| MEDLINE
| ID: mdl-11523403
ABSTRACT
AIM:
To evaluate the efficiency of combination of interferon-alpha (INF) and all trans-retinoic acid (ATRA) as a treatment for maintaining remission in high risk group patients with acute myeloid leukemia (AML). MATERIALS ANDMETHODS:
Three-day INF + ATRA course was administered every 3 months to 22 patients with AML from high risk group (impossibility of drug therapy during the first complete remission, resistant forms of AML, relapses, secondary AML, acute promyelocytic leukemia after attaining molecular remission).RESULTS:
INF + ATRA during remission maintained a long first complete remission (median 18 months) in patients with primary AML after small-volume drug therapy, led to long first and second complete remissions (median 12 months) in patients with resistant AML, and induced and maintained molecular remissions in patients with acute promyelocytic leukemia.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tretinoína
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Leucemia Mieloide
/
Interferon-alfa
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Ru
Revista:
Ter Arkh
Ano de publicação:
2001
Tipo de documento:
Article